RESUMEN
Objective:To investigate the effects of blood interleukin-6 (IL-6), red blood cell distribution width (RDW) and C-reactive protein (CRP) levels in the evaluation of the condition and prognosis of patients with moderate to severe acute pancreatitis (AP) and pulmonary infection.Methods:A total of 90 patients with moderate to severe AP combined with lung infection diagnosed and treated in Anhui Wanbei Coal and Electricity Group General Hospital from January 2018 to December 2020 were selected as the observation group, and 90 patients with moderate to severe AP without lung infection during the same period were selected as the control group. The IL-6, RDW, and CRP levels of patients in the two groups were compared, and their correlation with the disease severity was analyzed; the predictive value of serum IL-6, RDW and CRP levels on the prognosis of patients were analyzed by receiver operating characteristic (ROC) curve.Results:The serum levels of IL-6, RDW and CRP in the observation group were higher than those in the control group: (35.35 ± 7.19) ng/L vs. (26.91 ± 5.23) ng/L, (15.14 ± 5.36)% vs. (11.27 ± 2.07)%, (146.22 ± 50.27) mg/L vs. (102.83 ± 40.25) mg/L, and as the severity of the disease in the observation group increased, the serum IL-6, RDW and CRP levels increased, and the differences were statistically significant ( P<0.05). Serum IL-6, RDW, CRP levels of patients with moderate to severe AP combined with pulmonary infection were positively correlated with the severity of the disease ( r = 0.445, 0.610, 0.580, P<0.05). The serum levels of IL-6, RDW and CRP were higher in patients with poor prognosis when they were admitted to the hospital and on the 3rd and 7th days of admission than those with good prognosis ( P<0.05). The results of Cox regression analysis showed that serum IL-6, RDW and CRP levels at admission and on the 3rd and 7th day of admission were the prognostic factors of patients with moderate to severe AP combined with lung infection ( P<0.05). The combined detection of serum IL-6, RDW and CRP levels on the 7th day of admission had the largest area under the curve for predicting prognosis, and the sensitivity and specificity were 89.47% and 83.10%, respectively. Conclusions:The levels of serum IL-6, RDW and CRP in patients with moderate to severe AP combined with pulmonary infection are elevated, and are positively correlated with the severity of the disease. Clinical monitoring of their levels can provide a reliable reference for the formulation of treatment plans and prognostic evaluation.
RESUMEN
Objective The aim of the current study was to investigate the prognostic value of extracapsular lymph node spread in gastric cancer patients and to find correlations with clinicopathological parameters.Methods Clinicopathological data of 131 gastric cancer patients who underwent gastrectomy with lymphadenectomy were analyzed retrospectively. The number of metastatic lymph nodes with extracapsular spread were determined. Multivariate analysis was performed to find the clinical prognosis affecting extracapsular lymph node involvement. Results Seventy-eight patients (59.5%)had perigastric lymph node metastasis. Fortysix cases were detected extracapsular lymph node involvement. The 5-year cumulative survival rate for patients with extracapsular lymph node spread was 13. 5% , while 32 patients with lymph node metastasis but without extracapsular involvement had a 5-year survival rate of 39.3%. The survival rate decreased significantly with the increase of extracapsular lymph node involvement(P =0.001). Extracapsular lymph node involvement was significantly associated with the higher number of metastatic lymph nodes, the location of lymph node metastasis, tumor invasion depth and distant lymph node metastasis. In the multivariate analysis, extracapsular lymph node spread also remained as an independent prognostic factor(P =0.003). Conclusions Extracapsular lymph node involvement is a convenient and reliable prognostic index, and is an independent prognostic factor in gastric cancer patients. In future staging systems for gastric cancer, extracapsular lymph node involvement should be considered, be pathologically checked and reported in order to determine extracapsular spread status.
RESUMEN
Aim To identify paclitaxel differential binding protein in the cells of cell line MCF-7 and MCF-7/Taxol and to find new target for antitumor agents.Methods Synthesis and activity assay of biotinylated paclitaxel was used to gain paclitaxel binding protein by semiautomatic in vitro selection using the affinity magnetic beads method.LC MS/MS analysis and Western immunoblot analysis were used to identify the differential binding protein.Results The experimentation identified paclitaxel binding protein in the cells of MCF-7 and MCF-7/Taxol.An absent strap in MCF-7/Taxol was discovered by comparing the straps of two cell lines, which contained 25 kinds of proteins, among which 3 proteins were identified by western blot techniques: Heat shock protein HSP 90,Dermcidin Precursor,Actinin.Conclusions By comparing the straps of two cell lines, the differential protein in the cells of MCF-7 and MCF-7/Taxol are discovered, implying that they may be the novel mechanism of taxane resistance and may lead to find a new approach to finding a new target for oncotherapy drugs.
RESUMEN
Background and purpose:The prognosis of high grade gliomas remains poor, and multidisciplinary treatment strategy has been much investigated recently. This study was to explore the efficacy of Temozolomide as first-line treatment combined with radiotherapy and followed by adjuvant chemotherapy for the treatment of newly diagnosed high grade gliomas. Methods:18 patients who had been pathologically proven to be high grade gliomas were enrolled into the study. The patients received 40 Gy/20fractions for the whole brain and followed by 20Gy/10fractions as a boost to tumor bed. All of the patients were given daily oral temozolomide 75mg/ m2 during radiotherapy. 4 weeks after radiotherapy, all of the patients received 6 cycles of Temozolomide, each cycle lasted 5 days with 28 days interval between each cycles. 150 mg/m2 of temozolomide was given for the first cycle for five days,followd by 200 mg/m2 of drug for the rest of the cycles if no significant drug related toxicities were observed. Results:Median follow-up was 12.5 months, 11 cases had either recurrence or progression, 5 of them died from the disease. The median time for disease progression-free survival was 9.8 months (95% CI, 6.1~9.8months), the median time for overall survival was 14 months (95% CI, 8.5 ~ 19.5months), 1-year overall survival rate was 55.6% ,6-month progression-free survival rate was 81.8%. there were no severe temozolomide related toxicities. Conclusion: Concurrent temozolomide with radiotherapy and followed by 6 cycles of temozolomide in the treatment of high grade gliomas had better clinical efficacy, the patients tolerated the strategy well and no severe toxicities were observed.